Aspirin therapy can extend the life of colorectal cancer patients whose tumors carry a mutation in a key gene, but it has no effect on patients who lack the mutation, Harvard-affiliated Dana-Farber Cancer Institute scientists report in the Oct. 25 issue of the New England Journal of Medicine. “For the first time, we have a genetic marker that can help doctors determine which colorectal cancers are likely to respond to a particular therapy”, said the study’s senior author, Shuji Ogino of Dana-Farber, Brigham and Women’s Hospital, and the Harvard School of Public Health. Read more here.
Study mentioned: Xiaoyun L, et al. Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival. N Engl J Med 2012; 367:1596-1606.
No comments:
Post a Comment